24-Month Outcomes Following Transluminal Viscodilation of Schlemm’s Canal (ab-interno canaloplasty) for the Treatment of Open-Angle Glaucoma | ASCRS
Presentation
24-Month Outcomes Following Transluminal Viscodilation of Schlemm’s Canal (ab-interno canaloplasty) for the Treatment of Open-Angle Glaucoma
May 2020
Meeting: 2020 Virtual Annual Meeting
Session: SPS-105 Minimally Invasive Glaucoma Surgery: Viscocanalostomy, Combined Procedures, Outcomes
Author: Mark J. Gallardo, MD
This content is only available for ASCRS Members

This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.

Purpose
To investigate the safety and efficacy of ab interno iTrack canal based surgery (ABiC) in reducing intraocular pressure (IOP) and glaucoma medication use in eyes with primary open-angle glaucoma (POAG).

Methods
This was a single center, retrospective, non-randomized consecutive case series of eyes with POAG treated with ABiC as a stand-alone procedure or in conjunction with cataract extraction. Follow up visits were at 12 and 24 -months after surgery. The primary endpoints included mean IOP and mean number of glaucoma medications. Secondary endpoints included surgical and postsurgical complications and secondary interventions.

Results
The study included 60 eyes of 53 patients with a mean age of 73.6 ± 9.0 years. Baseline mean IOP was 20.7 ± 4.9 Hg on to 2.8 ± 0.9 medications. At 12 months after surgery, IOP and number of medications were statistically significantly (p<0.001) reduced to 13.6 ± 1.9 mmHg on 1.1 ± 1.1 medications. At 24 months after surgery, IOP was stable at 13.5 ± 2.6 mmHg on a slightly higher number of medications (1.7 ± 1.3). At 24-months, there was a mean IOP reduction of 34.8%, and a mean reduction in medications of 38.6%, and there was no difference in percentage reduction in IOP and in percentage reduction in medications between eyes that received ABiC alone and eyes that received combined treatment (p>0.05). However, the percentage reduction in medications was higher in the combined group (46.5%) than in the stand-alone group (31.4%). No serious adverse events were recorded.

Conclusion
These data demonstrate that ABiC was safe and efficient in reducing IOP and medication use over a 24-month follow-up in eyes with POAG treated with ABiC as a standalone procedure or with ABiC combined with cataract surgery.
View More Presentations from this Session

This presentation is from the session "SPS-105 Minimally Invasive Glaucoma Surgery: Viscocanalostomy, Combined Procedures, Outcomes" from the 2020 ASCRS Virtual Annual Meeting held on May 16-17, 2020.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.